Clinical trials
Oral Infection clinical trials
Below are recruiting oral infection clinical trials, each written for real people, not researchers. We’re tracking 68 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06355232RecruitingPhase 1
Oral vaccine for COVID-19 and flu
This study tests an experimental oral vaccine that may protect against both COVID-19 and the flu. Researchers want to see if it's safe and how the body responds.
Adelaide, South AustraliaAges 18 years+ - NCT07513285RecruitingPhase 2
Ibezapolstat pill for recurrent C. difficile infection
This trial tests a new oral antibiotic called ibezapolstat to treat recurrent C. difficile infection (CDI)—a serious diarrheal illness caused by bacteria in your gut. The study focuses on patients who have had multiple CDI episodes and may benefit from a different treatment approach.
Sacramento, CaliforniaAges 18–90 - NCT06979609RecruitingPhase 2/Phase 3
Preventing C. diff infection with vancomycin
This trial tests whether taking vancomycin by mouth can prevent another C. diff infection when you need to take other antibiotics. It’s for patients who recently had C. diff and are about to start a new antibiotic course.
Montreal, QuebecAges 18 years+ - NCT07851857RecruitingPhase 3
Short course of antibiotics after head and neck cancer surgery
This trial tests whether giving antibiotics for one day after head and neck surgery works just as well as giving them for longer to prevent infections. It might help you have a smoother recovery with fewer side effects from antibiotics.
São Paulo, São PauloAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT07616739RecruitingPhase 4
Dolutegravir and Lamivudine for Pregnant Women with HIV
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Ciudad Autónoma de Buenos Aires, Buenos AiresAges 15 years+ - NCT06953271RecruitingPhase 4
Methenamine after Botox for bladder control
This study tests whether taking a medication called methenamine hippurate (a pill for preventing UTIs) after Botox bladder injections can help reduce the risk of urinary tract infections. It may be a good option for women and non-binary people with overactive bladder who are already getting Botox treatment.
Providence, Rhode IslandAges 18 years+ - NCT07285785RecruitingPhase 4
Rifaximin for children with acute diarrhea
This study tests whether a medicine called rifaximin, taken along with oral rehydration solution, helps children aged 6 to 11 recover faster from acute (short-lasting) diarrhea that is likely caused by a bacterial infection. The study compares rifaximin plus oral rehydration versus oral rehydration alone.
Lynwood, CaliforniaAges 6–12 - NCT05224401RecruitingPhase 3
Oral antibiotic step-down for ESBL bladder infections
This Phase 3 trial tests whether switching from short-term IV antibiotics to an oral antibiotic combo is safe and effective for ESBL urine infections. It may help you avoid staying on IV antibiotics as long, if your bacteria are the right match.
HelsingborgAges 18–130 - NCT04527055Enrolling by invitationPhase 4
Bismuth treatment for H. pylori: 10 or 14 days
This trial compares two common stomach medicine plans that use bismuth for 10 days versus 14 days to clear an H. pylori infection. It may help you find a shorter or more effective treatment schedule if you have H. pylori confirmed by an endoscopy.
TainanAges 18–100 - NCT04665037RecruitingPhase 2
Posaconazole study for infants under 2 with serious fungal infection
This trial tests whether posaconazole, given through a vein or by mouth, can treat invasive fungal infections in children under 2 years old. It may help improve outcomes for infants with hard-to-treat fungal disease.
San Diego, CaliforniaAges 1 day–2 years - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT06859333RecruitingPhase 1
Safety study of Ingavirin Forte in healthy volunteers
This trial tests how safe and tolerable different doses of Ingavirin Forte are in healthy people. It helps find the right dose for future studies.
MoscowAges 18–45 - NCT06455852Recruiting
How well does the cholera vaccine protect you?
This study looks at how well the cholera vaccine and past infections protect people from getting cholera. It may help researchers understand who stays protected and for how long.
DhakaAges 2–80 - NCT05369052RecruitingPhase 3
New antibiotic for moderate or severe diabetic foot infections
This Phase 3 trial tests a new medicine (contezolid acefosamil, and contezolid) to treat moderate or severe diabetic foot infections. It compares the new treatment to linezolid to see which works better and is safer for adults.
Corona, CaliforniaAges 18 years+ - NCT06269679Recruiting
Comparing two dental x-rays one year after heart infection
This trial compares two types of dental X-rays (OPT and CBCT) to see which one better detects dental problems one year after a serious heart infection called infective endocarditis. It aims to help decide the best way to monitor your oral health after the infection.
BordeauxAges 18–100 - NCT06925321RecruitingPhase 3
Testing Fosmanogepix for Serious Mold Infections
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
Birmingham, AlabamaAges 18 years+ - NCT05492565Enrolling by invitation
Follow-up study for people on HIV prevention pills
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Seville, AndalusiaAges 18 years+ - NCT06509139Enrolling by invitationPhase 4
Finding the best treatment length for H. pylori infection
This study tests how long (10 or 14 days) a combination of four medicines (bismuth quadruple therapy) should be taken to best treat H. pylori infection, and whether the best duration differs between women and men. It aims to find the shortest effective treatment to reduce side effects.
TainanAges 18–100 - NCT06488846Enrolling by invitation
Giving HIV injections at home with a helper
This study tests whether having a trained friend or family member give you your HIV injections at home is safe and works as well as getting them at a clinic. You may qualify if you are already on the injectable HIV medication cabotegravir/rilpivirine (Cabenuva) and have a support person willing to help.
San Francisco, CaliforniaAges 18 years+ - NCT05303337Recruiting
Study of gut and HIV changes after switching to long-acting shots
This trial compares how HIV “reservoirs,” inflammation, and the gut microbiome change when people switch from daily HIV pills to long-acting injectable treatment. It may help you and your team understand what to expect with the switch and how your body responds.
MarseilleAges 18 years+
Hear when a new Oral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oral infection?
- Yes. Clin2 currently lists 68 recruiting oral infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oral infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oral infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.